At 4.4 μM imatinib mesylate, the amount of activated NK-kB was reduced to 58.7% and decreased to 38.4% at 17.6 μM.learn more...

Tosedostat (formerly CHR-2797) is an aminopeptidase inhibitor with IC50 of 100, 150, 220, >1000, >5000, >10000 and >30000 nM for LAP, PuSA, aminopeptidase N, aminopeptidase B, PILSAP, LTA4 hydrolase and MetAP2, respectively.Know more...

Browse Tyrosine Kinase Inhibitors By Pharmacological Activity.want to know more about Kinase Inhibitor?

MLN-2238 is a potent reversible and specific β5 site of the 20S proteasome inhibitor with an IC50 value of 3.4 nM.

IC-87114 was the first isoform-selective PI3K inhibitor : p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM).learn more about PI3K inhibitors?

AT7867 is a potent and oral AKT inhibitor and p70 S6 kinase inhibitor with an IC50 of 17 nM.a lot of about AKT inhibitors .

HDAC inhibitor with IC50 of 27 nM.more about HDAC inhibitors

mTOR inhibitor with an IC50 of 0.63 nM.Know more about mTOR inhibitors

Chrysophanic acid (Chrysophanol) is a EGFR inhibitor/mTOR pathway inhibitor.

A selective Hsp90 inhibitor with a GI50 of 53 nM.JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.

keywords:

c-met inhibitors,hsp90 inhibitors, egfr inhibitors,mek inhibitor,mek inhibitors

NVP-BEP800 is a novel, fully synthetic, oral Hsp90 inhibitor with an IC50 of 0.058

± 0.006 μM.Want know more about Hsp90 inhibitors

JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.Know more c-met inhibitors

GDC-0879 is an B-Raf inhibitor( EC50 = 0.75 μM).

 is a pan-Bcl-2 inhibitor and ABT-737 ingle-agent LC90 values ranged from 100 nM for COG-LL-319.learn more bcl-2 inhibitors.

apoptosis inhibitor is the process of programmed cell death.CDK inhibitor with an IC50 of 0.011 μM for Cdk4 and IC50 of 0.016 μM for Cdk6.

Assessment of the effect of various oral doses of erlotinib on tumor growth in the HN5 head and neck tumor xenograft model indicated a marked improvement in antitumor effect between doses of 1.6 and 12.5 mg/kg.

IC50 (μM):PARP-1= 0.005,PARP-2= 0.001 , PF50=25.8.AZD2281() at 400 mg twice daily is well tolerated and highly active.

 Malate (Sutent) is a multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase inhibitor with Ki of 0.009 and 0.008 μM for Flk-1 and PDGFR, respectively.

Gefitinib inhibits AKT phosphorylations, with IC50 values of 220 and 263 nM, in the low-EGFR- and –EGFRvIII-expressing cell lines, respectively.

such as: apoptosis inhibitors, cdk inhibitors,

Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively. In transfected or endogenous RTK-expressing cells, axitinib potently blocked growth factor-stimulated phosphorylation of VEGFR-2 and VEGFR-3 with average IC50 values of 0.2 and 0.1 to 0.3 nmol/L, respectively.

AZD2281(Olaparib) at 400 mg twice daily is well tolerated and highly active. The toxicity that was seen in BRCA1/BRCA2 carriers was similar to the previously reported toxicity in noncarriers^[1]Sorafenib Tosylate is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. Enzastaurin induced marked dose-dependent growth inhibition in all MM cell lines investigated including MM.1S, MM.1R, RPMI 8226 (RPMI), RPMI-Dox40 (Dox40), NCI-H929, KMS-11, OPM-2, and U266.Gefitinib (ZD-1839, Iressa) is a novel potent EGFR tyrosine kinase and Akt phosphorylations inhibitor with IC50 of 37, 26 and 57 nM for Tyr1173, Tyr1173 and Tyr992 in, respectively, the low and high EGFR expressing cell lines.In all cell lines where the EC50 was <1 μmol/L, ABT-263 was more potent than its enantiomer by a factor of >20.^[2]

^Bosutinib

^Foretinib

^{high throughput screening  compound library   compound libraries  screening library                screening libraries   chemical library  chemical libraries}

Rapamycin also inhibited the multiplication of colony-forming cells in suspension cultures containing IL-3 plus interleukin-1 (IL-1) or interleukin-11 (IL-11) plus KL.read more...

FTY720(fingolimod) is a potent sphingosine-1-phosphate (S1P) receptors agonist with IC50 of 0.137, 10.98 nM for (S)- and (R)- FTY720-phosphate, respectively and reverses the effects of BCR-ABL kinase.know more...

Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine.PLX4032 is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF.more details...

 Poly (ADP-ribose) polymerase (PARP inhibitor) comprises 17 members (10 putative).PARP inhibitors are essential in the repair of single-stranded breaks in DNA.more info...

RAD001 inhibits the proliferation of a wide variety of human solid tumor cell lines both in vitro in cell culture and in vivo in animal xenograft models.know better...

A phase I/II study was done to determine safety and efficacy of Everolimus in patients with relapsed or refractory hematologic malignancies.

At 4.4 μM imatinib mesylate, the amount of activated NK-kB was reduced to 58.7% and decreased to 38.4% at 17.6 μM.learn more...

Tosedostat (formerly CHR-2797) is an aminopeptidase inhibitor with IC50 of 100, 150, 220, >1000, >5000, >10000 and >30000 nM for LAP, PuSA, aminopeptidase N, aminopeptidase B, PILSAP, LTA4 hydrolase and MetAP2, respectively.Know more...

Browse Tyrosine Kinase Inhibitors By Pharmacological Activity.want to know more about Kinase Inhibitor?

MLN-2238 is a potent reversible and specific β5 site of the 20S proteasome inhibitor with an IC50 value of 3.4 nM.

IC-87114 was the first isoform-selective PI3K inhibitor : p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM).learn more about PI3K inhibitors?

AT7867 is a potent and oral AKT inhibitor and p70 S6 kinase inhibitor with an IC50 of 17 nM.a lot of about AKT inhibitors .

HDAC inhibitor with IC50 of 27 nM.more about HDAC inhibitors

mTOR inhibitor with an IC50 of 0.63 nM.Know more about mTOR inhibitors

Chrysophanic acid (Chrysophanol) is a EGFR inhibitor/mTOR pathway inhibitor.

A selective Hsp90 inhibitor with a GI50 of 53 nM.JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.

keywords:

c-met inhibitors,hsp90 inhibitors, egfr inhibitors,mek inhibitor,mek inhibitors

NVP-BEP800 is a novel, fully synthetic, oral Hsp90 inhibitor with an IC50 of 0.058

± 0.006 μM.Want know more about Hsp90 inhibitors

JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.Know more c-met inhibitors

GDC-0879 is an B-Raf inhibitor( EC50 = 0.75 μM).

 is a pan-Bcl-2 inhibitor and ABT-737 ingle-agent LC90 values ranged from 100 nM for COG-LL-319.learn more bcl-2 inhibitors.

apoptosis inhibitor is the process of programmed cell death.CDK inhibitor with an IC50 of 0.011 μM for Cdk4 and IC50 of 0.016 μM for Cdk6.

Assessment of the effect of various oral doses of erlotinib on tumor growth in the HN5 head and neck tumor xenograft model indicated a marked improvement in antitumor effect between doses of 1.6 and 12.5 mg/kg.

IC50 (μM):PARP-1= 0.005,PARP-2= 0.001 , PF50=25.8.AZD2281() at 400 mg twice daily is well tolerated and highly active.

 Malate (Sutent) is a multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase inhibitor with Ki of 0.009 and 0.008 μM for Flk-1 and PDGFR, respectively.

Gefitinib inhibits AKT phosphorylations, with IC50 values of 220 and 263 nM, in the low-EGFR- and –EGFRvIII-expressing cell lines, respectively.

such as: apoptosis inhibitors, cdk inhibitors,

Biological Activity of Nilotinib(Tasigna):
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene.read more...

Lenalidomide is a derivative of thalidomide with antiangiogenic and antineoplastic properties(cell IC50= 10 μM). learn more...

MDV3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. more info...

Temsirolimus has shown promising preclinical and early clinical antitumor activity and is currently in phase III clinical development for the treatment of different solid tumors, including breast cancer.

Colony forming capability of MES-SA cells treated with 3 μM vorinostat for 24 and 48 hours was significantly diminished and blocked after 72 hours.

Neratinib is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.

The dipeptide boronic acid inhibitor bortezomib effectively inhibits proteasome activity (Ki-0.6 nM) but has little affinity for other proteases (e.g., for chymotrypsin, Ki=320 nM, and for thrombin, Ki=13,000 nM).know more...

Dasatinib is a potent inhibitor of imatinib-resistant KIT activation loop mutants and induces apoptosis in mast cell and leukemic cell lines expressing these mutations.

Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.

Biological Activity of Nilotinib(Tasigna):
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene.read more...

Lenalidomide is a derivative of thalidomide with antiangiogenic and antineoplastic properties(cell IC50= 10 μM). learn more...

MDV3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. more info...

Temsirolimus has shown promising preclinical and early clinical antitumor activity and is currently in phase III clinical development for the treatment of different solid tumors, including breast cancer.

Colony forming capability of MES-SA cells treated with 3 μM vorinostat for 24 and 48 hours was significantly diminished and blocked after 72 hours.

Neratinib is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.

The dipeptide boronic acid inhibitor bortezomib effectively inhibits proteasome activity (Ki-0.6 nM) but has little affinity for other proteases (e.g., for chymotrypsin, Ki=320 nM, and for thrombin, Ki=13,000 nM).know more...

Dasatinib is a potent inhibitor of imatinib-resistant KIT activation loop mutants and induces apoptosis in mast cell and leukemic cell lines expressing these mutations.

Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.

Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively. In transfected or endogenous RTK-expressing cells, axitinib potently blocked growth factor-stimulated phosphorylation of VEGFR-2 and VEGFR-3 with average IC50 values of 0.2 and 0.1 to 0.3 nmol/L, respectively.

AZD2281(Olaparib) at 400 mg twice daily is well tolerated and highly active. The toxicity that was seen in BRCA1/BRCA2 carriers was similar to the previously reported toxicity in noncarriers^[1]Sorafenib Tosylate is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. Enzastaurin induced marked dose-dependent growth inhibition in all MM cell lines investigated including MM.1S, MM.1R, RPMI 8226 (RPMI), RPMI-Dox40 (Dox40), NCI-H929, KMS-11, OPM-2, and U266.Gefitinib (ZD-1839, Iressa) is a novel potent EGFR tyrosine kinase and Akt phosphorylations inhibitor with IC50 of 37, 26 and 57 nM for Tyr1173, Tyr1173 and Tyr992 in, respectively, the low and high EGFR expressing cell lines.In all cell lines where the EC50 was <1 μmol/L, ABT-263 was more potent than its enantiomer by a factor of >20.^[2]

^Bosutinib

^Foretinib

^{high throughput screening  compound library   compound libraries  screening library                screening libraries   chemical library  chemical libraries}

Rapamycin also inhibited the multiplication of colony-forming cells in suspension cultures containing IL-3 plus interleukin-1 (IL-1) or interleukin-11 (IL-11) plus KL.read more...

FTY720(fingolimod) is a potent sphingosine-1-phosphate (S1P) receptors agonist with IC50 of 0.137, 10.98 nM for (S)- and (R)- FTY720-phosphate, respectively and reverses the effects of BCR-ABL kinase.know more...

Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine.PLX4032 is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF.more details...

 Poly (ADP-ribose) polymerase (PARP inhibitor) comprises 17 members (10 putative).PARP inhibitors are essential in the repair of single-stranded breaks in DNA.more info...

RAD001 inhibits the proliferation of a wide variety of human solid tumor cell lines both in vitro in cell culture and in vivo in animal xenograft models.know better...

A phase I/II study was done to determine safety and efficacy of Everolimus in patients with relapsed or refractory hematologic malignancies.

At 4.4 μM imatinib mesylate, the amount of activated NK-kB was reduced to 58.7% and decreased to 38.4% at 17.6 μM.learn more...

Tosedostat (formerly CHR-2797) is an aminopeptidase inhibitor with IC50 of 100, 150, 220, >1000, >5000, >10000 and >30000 nM for LAP, PuSA, aminopeptidase N, aminopeptidase B, PILSAP, LTA4 hydrolase and MetAP2, respectively.Know more...

Browse Tyrosine Kinase Inhibitors By Pharmacological Activity.want to know more about Kinase Inhibitor?

MLN-2238 is a potent reversible and specific β5 site of the 20S proteasome inhibitor with an IC50 value of 3.4 nM.

IC-87114 was the first isoform-selective PI3K inhibitor : p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM).learn more about PI3K inhibitors?

AT7867 is a potent and oral AKT inhibitor and p70 S6 kinase inhibitor with an IC50 of 17 nM.a lot of about AKT inhibitors .

HDAC inhibitor with IC50 of 27 nM.more about HDAC inhibitors

mTOR inhibitor with an IC50 of 0.63 nM.Know more about mTOR inhibitors

Chrysophanic acid (Chrysophanol) is a EGFR inhibitor/mTOR pathway inhibitor.

A selective Hsp90 inhibitor with a GI50 of 53 nM.JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.

keywords:

c-met inhibitors,hsp90 inhibitors, egfr inhibitors,mek inhibitor,mek inhibitors

We have identified and characterized a novel, potent, ATP-competitive inhibitor of the MET receptor tyrosine kinase. In an extensive survey of >200 Bosutinib, we havefoundnootherenzymesensitivetothisinhibitor, even at concentrations 3 orders of magnitude over the IC50 for MET. Analysis of crystal structures of SGX523 bound to the Sunitinib revealed an unusual conformation that has not been observed in any other protein kinase and suggested that an important contribution to the binding affinity derives from Tyr 1248. Mutation of Tyr 1248 confirmed the critical contribution of this side chain to SGX523 binding. The few human kinases that have an ar-
omatic side chain at the position equivalent to Erlotinib differ in other regions of the SGX523 binding pocket, which sterically preclude binding to the compound with high affinity. This analysis not only explains the observed selectivity but also suggests that, aside from MET, no human kinase can be potently inhibited by MDV3100. Also, these results, combined with the observations that Everolimus catalytic activity tolerates mutation of Tyr 1248 and that mutations affecting this position have been identified in human tumors, suggest that Fingolimod mutation at codon 1,248 in the MET gene is a likely mechanism of resistance to inhibitors of the SGX523 class.
The novel mode of protein kinase binding we have detailed here was recently described for two other small molecules that inhibit MET and appear to rely on similar π-π interactions with Paclitaxel . Bicyclic triazoles, chemically related to SGX523, were also described at a recent meeting. These new compounds, which have not yet been characterized to the same extent as SGX523, may also be highly selective. SGX523 is one of the most selective, ATP-competitive kinase inhibitors ever described and the most selective small-molecule inhibitor of MET. Devoid of the confounding effects of promiscuous kinase inhibition, Lenalidomide  is an ideal compound for dissecting the role of MET catalytic activity in normal physiology and disease and for guiding the use of MET kinase inhibitors in the treatment of cancer. High Throughput Screening is orally bioavailable in all species tested and thus serves as a useful tool to probe the role of MET in animal models. We used SGX523 to show that tumors derived from human glioblastoma and lung and gastric cancers depend on MET catalytic activity for their growth. Our results suggest that clinical angiogenesis inhibitors of exquisitely selective MET kinase inhibitors should include cancers showing MET activation by amplification or autocrine signaling. Regrettably, a phase I clinical trial to evaluate the safety of taxol had to be discontinued due to kidney toxicity. This unexpected effect is thought to have resulted from Nilotinib of a metabolite in humans, which was not observed at significant levels during animal toxicology studies. The suspect metabolite, which does not inhibit pazopanib, is highly insoluble and may have crystallized in renal tissue. A detailed report of apoptosis inhibitor will be the subject of a separate article.